Alembic Pharmaceuticals Limited Q1 FY26 revenue increased by 10% to Rs. 1,711 crore, Profit Before Tax up by 21% to Rs. 191 crore and net profit at Rs. 154 crore up by 15%.

Commenting on the results, Pranav Amin, Alembic Pharmaceuticals Limited said, "We began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage."

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter. Good momentum in Specialty Therapies with Gynaecology, Cardiology, Anti-Diabetic, Ophthalmology and Animal healthcare segments demonstrating healthy growth. Anti-infective and Cough & Cold segments grew in line with represented market performance, with robust operational execution. Successfully introduced 3 new products during the quarter.

In the International Business, the US Generics grew by 13% to Rs. 523 crore for the quarter. Four Launches in the US market during the quarter. Ex-US International Generics grew by 21% to Rs. 328 crore for the quarter. Six ANDA approvals received during the quarter, 223 cumulative ANDA approvals, and API business grew by 1% to Rs. 261 crore for the quarter.